Newbury Pharmaceuticals
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.
Lapatinib Newbury approved by the Swedish Health Authorities
Newbury Pharmaceuticals is pleased to announce the Marketing Authorization (MA) of Lapatinib Newbury 250 mg film-coated tablets in Sweden as the first country in a Scandinavian registration procedure. Approvals in Norway and Denmark are expected to follow upon finalized national reviews.
Lapatinib is a targeted cancer drug, also known by its brand name Tyverb, that is used to treat certain types of breast cancer, where tumors overexpress HER2.
“Lapatinib is a terrific addition to the existing high-value oncology product portfolio, and we are proud to further strengthen our commitment within oncology. Based on this positive progress, we will proceed to launch this product, within respective markets as soon as regulatory exclusivities and patents allow us.” says Mr Lars Minor CEO of Newbury.
Newbury currently has licensed ten (10) products within oncology and plan to offer treatment options for both solid and hematological malignancies (e.g. breast cancer, myeloma, leukemia, prostate cancer and thyroid cancer).
| Datum | 2023-03-24, kl 11:45 |
| Källa | MFN |